Obsessive-compulsive symptoms induced by atypical anti-psychotics

2011 ◽  
Vol 26 (S2) ◽  
pp. 1220-1220
Author(s):  
A. Afkhamebrahimi
Keyword(s):  
Rating Scale ◽  
Obsessive Compulsive ◽  
Obsessive Compulsive Symptoms ◽  
Brief Psychiatric Rating Scale ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
The Mean ◽  
Psychiatric Rating Scale ◽  
In The Beginning ◽  
The Impact

ObjectiveThe impact of typical and atypical anti-psychotics on developing obsessive-compulsive symptoms in schizophrenic patients were investigated in this study.Materials and methods64 schizophrenic patients (32 cases in typical anti-psychotics group and 32 in atypical anti-psychotics group) participated in the study. All the patients first interviewed by SCID and then Yale Brown Obsessive-Compulsive Scale (Y-BOCS) and Brief psychiatric Rating Scale were administered in the beginning, 3 weeks and 6 weeks after treatment. The Data then transferred to SPSS program. for analysis.ResultsIn typical group the mean scores of Y-BOCS were 2.40, 2.30 and 2.18 in the beginning, 3 weeks and 6 weeks after treatment. In atypical group the mean scores of Y-BOCS were 4.12, 4.46 and 4.53 in three trials. There were no significant differences in the mean scores of Y-BOCS of two group in the beginning of the trial although a trend toward significance was observed but the differences between scores were significant in trial 2 (3 weeks) and trial 3 (6 weeks).DiscussionBased on this study and in line with previous studies, atypical anti-psychotics may induce obsessive compulsive symptoms (although mild) in patients with schizophrenia.

Use of Animals in the Rehabilitation of Psychiatric Inpatients

1986 ◽  
Vol 58 (1) ◽  
pp. 63-66 ◽  
Author(s):  
Alan M. Beck ◽  
Louisa Seraydarian ◽  
G. Frederick Hunter
Keyword(s):  
Rating Scales ◽  
Rating Scale ◽  
Psychiatric Inpatients ◽  
Brief Psychiatric Rating Scale ◽  
Psychiatric Rating Scales ◽  
Before And After ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
Activity Groups ◽  
The Impact

This study compared the impact of therapy and activity groups on two matched groups of 8 and 9 psychiatric inpatients. Daily sessions of the groups were held for 11 wk. in identical rooms except for the presence of caged finches in one of the rooms. The patients were evaluated before and after the sessions using standard psychiatric rating scales. The group who met in the room that contained animals (a cage with four finches) had significantly better attendance and participation and significantly improved in areas assessed by the Brief Psychiatric Rating Scale. Other positive trends indicated that the study should be replicated with larger samples and modified to increase interactions with the animals.

scholarly journals Electroconvulsive therapy in Parkinson´s disease

2015 ◽  
Vol 73 (10) ◽  
pp. 856-860 ◽  
Author(s):  
Humberto Calderón-Fajardo ◽  
Amin Cervantes-Arriaga ◽  
Rodrigo Llorens-Arenas ◽  
Jesús Ramírez-Bermudez ◽  
Ángel Ruiz-Chow ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Rating Scale ◽  
Neuropsychiatric Symptoms ◽  
Review Of The Literature ◽  
Scale Reduction ◽  
Brief Psychiatric Rating Scale ◽  
Psychiatric Rating ◽  
The Mean ◽  
Psychiatric Rating Scale ◽  
Therapy Sessions

Purpose To analyze the effectiveness of electroconvulsive therapy for the management of depression and/or psychosis refractory to drug therapy in patients with Parkinson disease.Methods A retrospective study was carried out including patients treated with electroconvulsive therapy during the period between 2002 and 2013. A review of the literature was performed.Results A total of 27 patients were included. In regards to the neuropsychiatric diagnosis, 14 patients had major depression, 12 patients had both psychosis and depression, and only one patient had isolated psychosis. The mean number of electroconvulsive therapy sessions was 12 ± 2.8. After electroconvulsive therapy, all patients showed a statistically significant improvement in the Brief Psychiatric Rating scale (reduction of 52% points) and Hamilton Depression Rating Scale (reduction of 50% points) independent of the presence of psychosis, depression or both.Conclusion Electroconvulsive therapy is effective for the treatment of refractory neuropsychiatric symptoms in Parkinson’s disease.

Baseline personality functioning correlates with 6 month outcome in schizophrenia

2003 ◽  
Vol 18 (3) ◽  
pp. 93-100 ◽  
Author(s):  
Secondo Fassino ◽  
Andrea Pierò ◽  
Elena Mongelli ◽  
Maria Luisa Caviglia ◽  
Nadia Delsedime ◽  
...  
Keyword(s):  
Personality Assessment ◽  
Multimodal Treatment ◽  
Rating Scale ◽  
Response To Treatment ◽  
Occupational Functioning ◽  
Personality Functioning ◽  
Brief Psychiatric Rating Scale ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale

AbstractObjectiveThe assessment of outcome in schizophrenic patients should consider both the response to treatment and the recovery of social skills. The aim was to evaluate the outcome and related psychostructural and clinical factors in schizophrenic patients after they underwent 6 months of residential multimodal treatment.MethodsFifty-two schizophrenic patients enrolled in a multimodal treatment program were included in the study. Symptomatology and social functioning were assessed with the Brief Psychiatric Rating Scale (BPRS) and the Social and Occupational Functioning Assessment Scale (SOFAS). The Karolinska Psychodynamic Profile (KAPP) was used for the psychostructural evaluation.ResultsAfter 6 months there was a significant improvement in the global scores of BPRS, SOFAS, and some areas of KAPP. The personality (KAPP) and social-occupational functioning (SOFAS) at baseline (T0) correlated with the global score of BPRS at 6 months (T6); moreover, SOFAS at T6 correlated with BPRS and KAPP at T0 and with the illness duration.ConclusionsThe better the personality functioning in schizophrenic patients the better seems to be the response to treatment, with regard to symptoms as well as rehabilitation. Personality assessment might be useful for the individualisation of therapies, even within the context of a standardised program.

Behavioural Family Management in Schizophrenia

1994 ◽  
Vol 164 (4) ◽  
pp. 501-506 ◽  
Author(s):  
Eugenia T. Randolph ◽  
Spencer Eth ◽  
Shirley M. Glynn ◽  
George G. Paz ◽  
Gregory B. Leong ◽  
...  
Keyword(s):  
Rating Scale ◽  
Health Clinic ◽  
Controlled Study ◽  
Veterans Administration ◽  
Family Management ◽  
First Year ◽  
Brief Psychiatric Rating Scale ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale

To test further the highly successful outcomes of a controlled study of in-home behavioural family management (BFM) for schizophrenic patients, a clinic-based version of this intervention was compared with customary care alone for 41 schizophrenic patients in a Veterans Administration (VA) mental health clinic. Monthly Brief Psychiatric Rating Scale (BPRS) ratings, conducted by clinic psychiatrists who were ‘blind’ to the patients' assignment, revealed that 3 (14%) patients who received behavioural family management as well as customary care, as compared with 11 (55%) patients who received customary care alone, had symptomatic exacerbations during the first year of treatment.

Adequacy of the Brief Psychiatric Rating Scale for Distinguishing Lesser Forms of Psychopathology

1977 ◽  
Vol 40 (1) ◽  
pp. 167-173 ◽  
Author(s):  
Charles B. Pull ◽  
John E. Overall
Keyword(s):  
Rating Scale ◽  
Full Range ◽  
Obsessive Compulsive ◽  
Brief Psychiatric Rating Scale ◽  
Clinical Syndromes ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
Outpatient Settings ◽  
And Behavior ◽  
Syndrome Patterns

The adequacy of the Brief Psychiatric Rating Scale for distinguishing among lesser forms of psychopathology, as well as among the more serious forms, was investigated. 31 psychiatrists provided symptom descriptions for 13 clinical syndromes which were selected to span the full range of inpatient and outpatient psychopathology. The symptom descriptions included, in addition to the standard 18 scales of the rating scale, 24 additional symptom- and behavior-rating constructs. It was found that the syndrome patterns could be distinguished with high accuracy in terms of the 18 variables of the rating scale alone. The only distinction that was enhanced by consideration of additional scales was the obsessive-compulsive versus phobic syndrome distinction. On the basis of these results, it is concluded that the Brief Psychiatric Rating Scale should be considered useful for description of psychopathology in outpatient settings even though most of the developmental work on the instrument was done in inpatient research.

Negative and Depressive Symptoms in Schizophrenia

1989 ◽  
Vol 154 (2) ◽  
pp. 207-211 ◽  
Author(s):  
Parmanand Kulhara ◽  
Ajit Avasthi ◽  
Rakesh Chadda ◽  
Kishore Chandiramani ◽  
Surendra K. Mattoo ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Negative Symptoms ◽  
Rating Scale ◽  
Symptoms Of Depression ◽  
Brief Psychiatric Rating Scale ◽  
Significant Relationships ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
Depressive Syndromes

Ninety-five schizophrenic patients were assessed using the Present State Examination, the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms. Negative and depressive symptoms were frequent, and significant relationships among negative symptom complexes and depressive syndromes were noted. Retardation, lack of energy, slowness, and other symptoms of depression were significantly associated with the negative symptoms of schizophrenia. Depressed affect per se did not have a significant correlation with negative symptoms.

The Effect of Thioridazine on Prolactin Levels in Actutely Schizophrenic Patients: Challenge-Dose and Steady-State Levels

1980 ◽  
Vol 14 (2) ◽  
pp. 127-131 ◽  
Author(s):  
G. F. S. Johnson ◽  
G. E. Hunt
Keyword(s):  
Steady State ◽  
Rating Scale ◽  
Challenge Dose ◽  
Duration Of Treatment ◽  
Brief Psychiatric Rating Scale ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Steady State Levels ◽  
Male Patients ◽  
Psychiatric Rating Scale

Prolactin (PRL) levels in unmedicated male patients with acute schizophrenia were within normal range at baseline, increased five fold after a challenge dose of thioridazine, did not significantly increase further after therapeutic dosages, and remained elevated for the duration of treatment. The rise in PRL levels was significantly correlated with the steady-state plasma levels of thioridazine and/or mesoridazine. Baseline and challenge-dose PRL levels did not correlate with severity of symptoms as measured by the Brief Psychiatric Rating Scale, or predict response to thioridazine. Overall, there was a trend for the drug and PRL levels to increase very quickly and remain elevated while the clinical response was gradual over the four-week period. Clinically, it may be useful monitoring PRL levels, since the therapeutic dosage should usually be above the dosage required to produce maximal PRL levels.

The Neuroleptic Hypothesis: Study of the Covariation of Extrapyramidal and Therapeutic Drug Effects

1978 ◽  
Vol 133 (2) ◽  
pp. 169-175 ◽  
Author(s):  
M. Alpert ◽  
F. Diamond ◽  
J. Weisenfreund ◽  
E. Taleporos ◽  
A. J. Friedhoff
Keyword(s):  
Rating Scale ◽  
Drug Effects ◽  
Fixed Dose ◽  
Therapeutic Drug ◽  
Therapeutic Trial ◽  
Brief Psychiatric Rating Scale ◽  
Dopamine Hypothesis ◽  
Schizophrenic Patients ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale

SummaryA therapeutic trial with chlorpromazine was conducted with a homogeneous (for age and sex) group of recently admitted schizophrenic patients. Extrapyramidal effects were measured through quantitative analysis of digital tremor, after four days of fixed-dose treatment. Assessment of treatment efficacy was based on Brief Psychiatric Rating Scale ratings, done at the end of four weeks' treatment. Those patients whose tremor was least affected by drug were most likely to benefit from the treatment. Implications of this negative correlation for our understanding of the neuroleptic hypothesis and the closely associated dopamine hypothesis of schizophrenia are discussed.

scholarly journals Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia

2020 ◽  
Vol 18 (3) ◽  
pp. 293-300
Author(s):  
Arash Mirabzadeh ◽  
◽  
Hamid Reza Iranpour ◽  
Hamid Reza Khorram Khorshid ◽  
Davood Zare-Abdollahi ◽  
...  
Keyword(s):  
Peripheral Blood ◽  
Rating Scale ◽  
Response To Treatment ◽  
Brief Psychiatric Rating Scale ◽  
Genes Expression ◽  
Schizophrenic Patients ◽  
History Of ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
Care Costs

Objectives: Schizophrenia is a severe psychiatric disorder that has profound effects on both individuals and the community. Notwithstanding the suggestion for treating schizophrenia with a minimum dose of drugs, antipsychotic polypharmacy increases the patient’s care costs and drug interactions. Aripiprazole reduces the metabolic side effects of antipsychotic polypharmacy treatment. DRD2 and HTR2A can serve as predictors for response to treatment in schizophrenic patients. The purpose of this survey was to measure the DRD2 and HTR2A genes expression in the peripheral blood samples using Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). Methods: A total of 19 patients with a long history of schizophrenia who received at least two types of antipsychotics with daily doses of more than 500 mg of chlorpromazine were entered into the study. The response rates to the treatment based on scores in the Brief Psychiatric Rating Scale (BPRS) questionnaire and DRD2 and HTR2A expression were compared between antipsychotic polypharmacy status and 6 months after monotherapy with aripiprazole. Results: The levels of DRD2 expression decreased significantly after the intervention. The mean changes in HTR2A expression and the BPRS questionnaire and also the relationship between changes in DRD2 and HTR2A expression and changes in BPRS score after the intervention were not significant. Discussion: The conversion of the antipsychotic polypharmacy state to monotherapy with aripiprazole has been accompanied by a significant decrease in DRD2A expression. These genes can be used for evaluating the response rate of schizophrenia treatments in the future.

Sign in / Sign up

Export Citation Format

Share Document